Landing
Manuscripts
The following information for US healthcare professionals includes links to Apellis-sponsored clinical trials that have been published in peer reviewed journals. The list of publications below may contain information about doses, uses, formulations and populations different from product labeling or contain information about investigational compounds or uses not approved by a regulatory authority. The following list of publications is not comprehensive or exhaustive as to any particular topic. Apellis does not suggest or recommend the use of its products in any manner other than as described in the Prescribing Information. Please refer to the product’s Full Prescribing Information.
Select a disease area
By expanding you’re confirming that your query is unsolicited.
Comparative Analysis of Proteinuria and Longitudinal Outcomes in Immune Complex Membranoproliferative Glomerulonephritis and C3 Glomerulopathy
Caravaca-Fontan F, Toledo-Rojas, R, Huerta, A, et al. Comparative Analysis of Proteinuria and Longitudinal Outcomes in Immune Complex Membranoproliferative Glomerulonephritis and C3 Glomerulopathy. Kidney International Reports. 2025. doi: 10.1016/j.ekir.2025.01.024
C3G
Clinical Safety and Efficacy of Pegcetacoplan in a Phase 2 Study of Patients with C3 Glomerulopathy and Other Complement-Mediated Glomerular Diseases.
Dixon B, Greenbaum LA, Huang L, et al. Clinical Safety and Efficacy of Pegcetacoplan in a Phase 2 Study of Patients with C3 Glomerulopathy and Other Complement-Mediated Glomerular Diseases. Kidney International Reports. 2023. doi: 10.1016/j.ekir.2023.08.033
C3G
Efficacy and Safety of Pegcetacoplan in Kidney Transplant Recipients With Recurrent Complement 3 Glomerulopathy or Primary Immune Complex Membranoproliferative Glomerulonephritis
Bomback, A, Daina, E, Remuzzi, G, et al. Efficacy and Safety of Pegcetacoplan in Kidney Transplant Recipients With Recurrent Complement 3 Glomerulopathy or Primary Immune Complex Membranoproliferative Glomerulonephritis. Kidney International Reports. 2025. DOI: 10.1016/j.ekir.2024.09.030
C3G
Novel Complement Therapeutics in Development as Potential Treatment for Renal Disease
Kelleher C, Kocinsky H. Novel Complement Therapeutics in Development as Potential Treatment for Renal Disease. Adv Chronic Kidney Dis. 2020;27(2):95-103. doi:10.1053/j.ackd.2020.02.006
C3G
Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials
Heier JS, Lad EM, Holz FG, et al. Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials. Lancet. 2023;402(10411):1434-1448. doi:10.1016/S0140-6736(23)01520-9
Geographic
Pegcetacoplan for the treatment of geographic atrophy due to age-related macular degeneration: a plain language summary of OAKS and DERBY clinical studies
Heier JS, Lad EM, Holz FG, et al. Pegcetacoplan for the treatment of geographic atrophy due to age-related macular degeneration: a plain language summary of OAKS and DERBY clinical studies. Immunotherapy. 2025;1–15. Advance online publication. doi:10.1080/1750743X.2025.2449760
Geographic
Disease Activity and Therapeutic Response to Pegcetacoplan for Geographic Atrophy Identified by Deep Learning-Based Analysis of OCT
Schmidt-Erfurth U, Mai J, Reiter GS, et al. Disease Activity and Therapeutic Response to Pegcetacoplan for Geographic Atrophy Identified by Deep Learning-Based Analysis of OCT. Ophthalmology. 2025;132(2):181-193. doi:10.1016/j.ophtha.2024.08.017
Geographic
Visual Function Benefit After Treatment With Pegcetacoplan: Microperimetry Analysis From the Phase 3 Oaks Trial
Chakravarthy U, Schwartz R, Guymer RH, et al. Visual Function Benefit After Treatment With Pegcetacoplan: Microperimetry Analysis From the Phase 3 Oaks Trial. Am J Ophthalmol. 2025;273:119-129. Advance online publication. doi:10.1016/j.ajo.2025.02.012
Geographic
Outer Retinal Tubulation and Vision in Geographic Atrophy: A Natural History Analysis From the Phase 3 OAKS and DERBY Trials
Hatcher KA, Shah BK, Yu S, Baumal CR, Sadda S. Outer Retinal Tubulation and Vision in Geographic Atrophy: A Natural History Analysis From the Phase 3 OAKS and DERBY Trials. Ophthalmic Surg Lasers Imaging Retina. 2025;1–3. Advance online publication. doi:10.3928/23258160-20250108-02
Geographic
Real-World Healthcare Resource Utilization, Healthcare Costs, and Injurious Falls Among Elderly Patients with Geographic Atrophy
Sarda SP, Germain G, Mahendran M, et al. Real-World Healthcare Resource Utilization, Healthcare Costs, and Injurious Falls Among Elderly Patients with Geographic Atrophy. Clin Ophthalmol. 2024;18:3215-3226. doi:10.2147/OPTH.S475331
Geographic
Geographic atrophy and factors associated with disease progression among Medicare Advantage enrollees
Saundankar V, Borns M, Broderick K, et al. Geographic atrophy and factors associated with disease progression among Medicare Advantage enrollees. J Manag Care Spec Pharm. 2025;31(1):42-52. doi:10.18553/jmcp.2025.31.1.42
Geographic
Longitudinal Changes of Visual Sensitivity With Geographic Atrophy Progression Assessed by Defect-Mapping Microperimetry
Saeed A, Guymer RH, Hadoux X, et al. Longitudinal Changes of Visual Sensitivity With Geographic Atrophy Progression Assessed by Defect-Mapping Microperimetry. Invest Ophthalmol Vis Sci. 2024;65(14):13. doi:10.1167/iovs.65.14.13
Geographic
Functional Outcomes and Quality of Life in Geographic Atrophy in the Clinical Setting
Borkar D, Rahimy E, Khan MA, et al. Functional Outcomes and Quality of Life in Geographic Atrophy in the Clinical Setting. Ophthalmol Retina. 2024;S2468-6530(24)00543-8. Advance online publication. doi:10.1016/j.oret.2024.11.013
Geographic
The MOSAIC Study: A Mixed-Methods Study of the Clinical, Emotional, and Financial Burden of Geographic Atrophy Among Patients and Caregivers in the US
Bakri SJ, Amoaku WMK, Altman D, et al. The MOSAIC Study: A Mixed-Methods Study of the Clinical, Emotional, and Financial Burden of Geographic Atrophy Among Patients and Caregivers in the US. Clin Ophthalmol. 2024;18:2357-2368. doi:10.2147/OPTH.S455984
Geographic
Evaluating the reliability of a microperimetry-based method for assessing visual function in the junctional zone of geographic atrophy lesions
Alibhai AY, Moult EM, Jamil MU, et al. Evaluating the reliability of a microperimetry-based method for assessing visual function in the junctional zone of geographic atrophy lesions. Int J Retina Vitreous. 2025;11(1):1. doi:10.1186/s40942-024-00624-7
Geographic
Annual prevalence of geographic atrophy and wet age-related macular degeneration among Medicare Advantage enrollees in a US health plan
Saundankar V, Borns M, Broderick K, et al. Annual prevalence of geographic atrophy and wet age-related macular degeneration among Medicare Advantage enrollees in a US health plan. J Manag Care Spec Pharm. 2025;31(1):88-94. doi:10.18553/jmcp.2025.31.1.88
Geographic
Longitudinal Changes of Visual Sensitivity With Geographic Atrophy Progression Assessed by Defect-Mapping Microperimetry
Saeed A, Guymer RH, Hadoux X, et al. Longitudinal Changes of Visual Sensitivity With Geographic Atrophy Progression Assessed by Defect-Mapping Microperimetry. Invest Ophthalmol Vis Sci. 2024;65(14):13. doi:10.1167/iovs.65.14.13
Geographic
Pharmacokinetic/pharmacodynamic analysis of geographic atrophy lesion area in patients receiving pegcetacoplan treatment or sham
Crass RL, Prem K, Gaudreault F, et al. Pharmacokinetic/pharmacodynamic analysis of geographic atrophy lesion area in patients receiving pegcetacoplan treatment or sham. CPT Pharmacometrics Syst Pharmacol. 2025;14(2):257-267. doi:10.1002/psp4.13264
Geographic
Population Pharmacokinetics of Pegcetacoplan in Patients with Geographic Atrophy or Neovascular Age-related Macular Degeneration
Crass RL, Prem K, Gauderault F, et al. Population Pharmacokinetics of Pegcetacoplan in Patients with Geographic Atrophy or Neovascular Age-related Macular Degeneration. Ophthalmol Sci. 2024;5(2):100657. doi:10.1016/j.xops.2024.100657
Geographic
A Novel Management Challenge in Age-Related Macular Degeneration: Artificial Intelligence and Expert Prediction of Geographic Atrophy
Reiter GS, Lachinov D, Bühl W, et al. A Novel Management Challenge in Age-Related Macular Degeneration: Artificial Intelligence and Expert Prediction of Geographic Atrophy. Ophthalmol Retin. 2024;S2468-6530(24)00532-3. Advance online publication. doi:10.1016/j.oret.2024.10.029
Geographic
Outer Retinal Tubulation in Geographic Atrophy
Hatcher KA, Shah BK, Burch M, Kondapalli SSA, Baumal CR. Outer Retinal Tubulation in Geographic Atrophy. Ophthalmic Surg Lasers Imaging Retina. 2024;55(8):448-451. doi:10.3928/23258160-20240411-02
Geographic
Pegcetacoplan Treatment and Consensus Features of Geographic Atrophy Over 24 Months
Fu DJ, Bagga P, Naik G, et al. Pegcetacoplan Treatment and Consensus Features of Geographic Atrophy Over 24 Months. JAMA Ophthalmol. 2024;142(6):548-558. doi:10.1001/jamaophthalmol.2024.1269
Geographic
Epidemiology of Diagnosed Age-related Macular Degeneration in Germany: An Evaluation of the Prevalence Using AOK PLUS Claims Data
Schuster AK, Leisle L, Picker N, et al. Epidemiology of Diagnosed Age-related Macular Degeneration in Germany: An Evaluation of the Prevalence Using AOK PLUS Claims Data. Ophthalmol Ther. 2024;13(4):1025-1039. doi:10.1007/s40123-024-00901-6
Geographic
Visual Sensitivity Loss in Geographic Atrophy: Structure-Function Evaluation Using Defect-Mapping Microperimetry
Wu Z, Hadoux X, Jannaud M, et al. Visual Sensitivity Loss in Geographic Atrophy: Structure-Function Evaluation Using Defect-Mapping Microperimetry. Invest Ophthalmol Vis Sci. 2024;65(1):36. doi:10.1167/iovs.65.1.36
Geographic
Patient acceptability of intravitreal complement inhibitors in geographic atrophy (GA): protocol for a UK-based cross-sectional study
Dinah C, Enoch J, Ghulakhszian A, Sekhon M, Crabb DP, Taylor DJ. Patient acceptability of intravitreal complement inhibitors in geographic atrophy (GA): protocol for a UK-based cross-sectional study. BMJ Open. 2024;14(1):e075713. doi:10.1136/bmjopen-2023-075713
Geographic
Progression of Geographic Atrophy: Retrospective Analysis of Patients from the IRIS® Registry (Intelligent Research in Sight)
Rahimy E, Khan MA, Ho AC, et al. Progression of Geographic Atrophy: Retrospective Analysis of Patients from the IRIS® Registry (Intelligent Research in Sight). Ophthalmol Sci. 2023;3(4):100318. doi:10.1016/j.xops.2023.100318
Geographic
Diagnosis and Management of Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Delphi Consensus Exercise
Singh RP, Amoaku W, Bandello F, et al. Diagnosis and Management of Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Delphi Consensus Exercise. Ophthalmic Surg Lasers Imaging Retina. 2023;54(10):589-598. doi:10.3928/23258160-20230824-01
Geographic
Evaluating the Effects of C3 Inhibition on Geographic Atrophy Progression from Deep-Learning OCT Quantification: A Split-Person Study
Fu DJ, Lipkova V, Liefers B, et al. Evaluating the Effects of C3 Inhibition on Geographic Atrophy Progression from Deep-Learning OCT Quantification: A Split-Person Study. Ophthalmol Ther. 2023;12(6):3143-3158. doi:10.1007/s40123-023-00798-7
Geographic
Piloting a forced-choice task to elicit treatment preferences in geographic atrophy
Enoch J, Ghulakhszian A, Sekhon M, Crabb DP, Taylor DJ, Dinah C. Piloting a forced-choice task to elicit treatment preferences in geographic atrophy. BMC Res Notes. 2023;16(1):244. doi:10.1186/s13104-023-06531-8
Geographic
Exploring patient acceptability of emerging intravitreal therapies for geographic atrophy: A mixed-methods study
Enoch J, Ghulakhszian A, Sekhon M, Crabb DP, Taylor DJ, Dinah C. Exploring patient acceptability of emerging intravitreal therapies for geographic atrophy: A mixed-methods study. Eye (Lond). 2023;37(17):3634-3642. doi:10.1038/s41433-023-02571-3
Geographic
Geographic atrophy: Mechanism of disease, pathophysiology, and role of the complement system
Bakri SJ, Bektas M, Sharp D, Luo R, Sarda SP, Khan S. Geographic atrophy: Mechanism of disease, pathophysiology, and role of the complement system. J Manag Care Spec Pharm. 2023;29(5-a Suppl):S2-S11. doi:10.18553/jmcp.2023.29.5-a.s2
Geographic
Clinical validation for automated geographic atrophy monitoring on OCT under complement inhibitory treatment
Mai J, Lachinov D, Riedl S, et al. Clinical validation for automated geographic atrophy monitoring on OCT under complement inhibitory treatment. Sci Rep. 2023;13(1):7028. doi:10.1038/s41598-023-34139-2
Geographic
Deep-learning automated quantification of longitudinal OCT scans demonstrates reduced RPE loss rate, preservation of intact macular area and predictive value of isolated photoreceptor degeneration in geographic atrophy patients receiving C3 inhibition treatment
Fu DJ, Glinton S, Lipkova V, et al. Deep-learning automated quantification of longitudinal OCT scans demonstrates reduced RPE loss rate, preservation of intact macular area and predictive value of isolated photoreceptor degeneration in geographic atrophy patients receiving C3 inhibition treatment. Br J Ophthalmol. 2024;108(4):536-545. doi:10.1136/bjo-2022-322672
Geographic
Towards a Therapy for Geographic Atrophy: A Patient’s Experience
Enoch J, Ghulakhszian A, Sekhon M, Crabb DP, Taylor DJ, Dinah C. Towards a Therapy for Geographic Atrophy: A Patient’s Experience. Patient Prefer Adherence. 2023;17:299-310. doi:10.2147/PPA.S386662
Geographic
Predicting Topographic Disease Progression and Treatment Response of Pegcetacoplan in Geographic Atrophy Quantified by Deep Learning
Vogl WD, Riedl S, Mai J, et al. Predicting Topographic Disease Progression and Treatment Response of Pegcetacoplan in Geographic Atrophy Quantified by Deep Learning. Ophthalmol Retina. 2023;7(1):4-13. doi:10.1016/j.oret.2022.08.003
Geographic
Comparison of Fundus Autofluorescence Versus Optical Coherence Tomography-based Evaluation of the Therapeutic Response to Pegcetacoplan in Geographic Atrophy
Mai J, Riedl S, Reiter GS, et al. Comparison of Fundus Autofluorescence Versus Optical Coherence Tomography-based Evaluation of the Therapeutic Response to Pegcetacoplan in Geographic Atrophy. Am J Ophthalmol. 2022;244:175-182. doi:10.1016/j.ajo.2022.06.023
Geographic
Association of complement C3 inhibitor pegcetacoplan with reduced photoreceptor degeneration beyond areas of geographic atrophy
Pfau M, Schmitz-Valckenberg S, Ribeiro R, et al. Association of complement C3 inhibitor pegcetacoplan with reduced photoreceptor degeneration beyond areas of geographic atrophy. Sci Rep. 2022;12(1):17870. doi:10.1038/s41598-022-22404-9
Geographic
Prediction of visual function from automatically quantified optical coherence tomography biomarkers in patients with geographic atrophy using machine learning
Balaskas K, Glinton S, Keenan TDL, et al. Prediction of visual function from automatically quantified optical coherence tomography biomarkers in patients with geographic atrophy using machine learning. Sci Rep. 2022;12(1):15565. doi:10.1038/s41598-022-19413-z
Geographic
Pegcetacoplan treatment for geographic atrophy due to age-related macular degeneration: a plain language summary of the FILLY study
Liao DS, Metlapally R, Joshi P. Pegcetacoplan treatment for geographic atrophy due to age-related macular degeneration: a plain language summary of the FILLY study. Immunotherapy. 2022;14(13):995-1006. doi:10.2217/imt-2022-0078
Geographic
Association of Pegcetacoplan With Progression of Incomplete Retinal Pigment Epithelium and Outer Retinal Atrophy in Age-Related Macular Degeneration: A Post Hoc Analysis of the FILLY Randomized Clinical Trial
Nittala MG, Metlapally R, Ip M, et al. Association of Pegcetacoplan With Progression of Incomplete Retinal Pigment Epithelium and Outer Retinal Atrophy in Age-Related Macular Degeneration: A Post Hoc Analysis of the FILLY Randomized Clinical Trial. JAMA Ophthalmol. 2022;140(3):243-249. doi:10.1001/jamaophthalmol.2021.6067
Geographic
Characterizing New-Onset Exudation in the Randomized Phase 2 FILLY Trial of Complement Inhibitor Pegcetacoplan for Geographic Atrophy
Wykoff CC, Rosenfeld PJ, Waheed NK, et al. Characterizing New-Onset Exudation in the Randomized Phase 2 FILLY Trial of Complement Inhibitor Pegcetacoplan for Geographic Atrophy. Ophthalmology. 2021;128(9):1325-1336. doi:10.1016/j.ophtha.2021.02.025
Geographic
Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial
Liao DS, Grossi FV, El Mehdi D, et al. Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial. Ophthalmology. 2020;127(2):186-195. doi:10.1016/j.ophtha.2019.07.011
Geographic
Humanistic and Economic Burden of Geographic Atrophy: A Systematic Literature Review
Sarda SP, Heyes A, Bektas M, et al. Humanistic and Economic Burden of Geographic Atrophy: A Systematic Literature Review. Clin Ophthalmol. 2021;15:4629-4644. doi:10.2147/OPTH.S338253
Geographic
Impact of Baseline Characteristics on Geographic Atrophy Progression in the FILLY Trial Evaluating the Complement C3 Inhibitor Pegcetacoplan
Steinle NC, Pearce I, Monés J, et al. Impact of Baseline Characteristics on Geographic Atrophy Progression in the FILLY Trial Evaluating the Complement C3 Inhibitor Pegcetacoplan. Am J Ophthalmol. 2021;227:116-124. doi:10.1016/j.ajo.2021.02.031
Geographic
Inside-Out of Complement in Cancer
Kolev M, Das M, Gerber M, Baver S, Deschatelets P and Markiewski MM (2022) Inside-Out of Complement in Cancer. Front. Immunol. 13:931273. doi: 10.3389/fimmu.2022.931273
Oncology
Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
Hillmen P, Szer J, Weitz I, et al. (2021) Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria. N Engl J Med. 384(11):1028-1037. doi:10.1056/NEJMoa2029073
Paroxysmal
Plain language summary of PEGASUS, a study comparing pegcetacoplan with eculizumab for 16 weeks in people with paroxysmal nocturnal hemoglobinuria
Griffin M, Szer J, Weitz I, et al. (2023) Plain language summary of PEGASUS, a study comparing pegcetacoplan with eculizumab for 16 weeks in people with paroxysmal nocturnal hemoglobinuria. Future Rare Diseases. 3:3. doi: 10.2217/frd-2023-0005
Paroxysmal
Pegcetacoplan controls hemolysis in complement inhibitor–naive patients with paroxysmal nocturnal hemoglobinuria
Wong RSM, Navarro-Cabrera JR, Comia NS, et al. (2023). Pegcetacoplan controls hemolysis in complement inhibitor–naive patients with paroxysmal nocturnal hemoglobinuria. Blood Advances, 7 (11): 2468–2478. doi: https://doi.org/10.1182/bloodadvances.2022009129
Paroxysmal
Pegcetacoplan compared with supportive care for 26 weeks for participants with paroxysmal nocturnal hemoglobinuria: a plain language summary
Wong RSM, Navarro-Cabrera JR, Comia NS, et al. (2023). Pegcetacoplan compared with supportive care for 26 weeks for participants with paroxysmal nocturnal hemoglobinuria: a plain language summary. Future Rare Diseases, Epub ahead of print. doi: 10.2217/frd-2023-0006
Paroxysmal
Real-World Study of US Adults with Paroxysmal Nocturnal Hemoglobinuria Treated with Pegcetacoplan
Mulherin B, Shenoy A, Arnett L, et al. (2024). Real-World Study of US Adults with Paroxysmal Nocturnal Hemoglobinuria Treated with Pegcetacoplan. Hematology Reports, 16(4), 669-681. doi:10.3390/hematolrep16040065
Paroxysmal
Fatigue and health-related quality of life in paroxysmal nocturnal haemoglobinuria: A post hoc analysis of the pegcetacoplan PEGASUS trial data
Panse J, Wilson K, Fishman J, et al. (2023). Fatigue and health-related quality of life in paroxysmal nocturnal haemoglobinuria: A post hoc analysis of the pegcetacoplan PEGASUS trial data. Eur J Haematol, 111:72–83. doi: 10.1111/ejh.13969
Paroxysmal
Injection Site Reactions with Long-Term Pegcetacoplan Use in Patients with Paroxysmal Nocturnal Hemoglobinuria: A Brief Report
Sharma V, Koprivnikar J, Drago K, et al. (2023). Injection Site Reactions with Long-Term Pegcetacoplan Use in Patients with Paroxysmal Nocturnal Hemoglobinuria: A Brief Report. Adv Ther, 40(11):5115-5129. doi: 10.1007/s12325-023-02653-4
Paroxysmal
Descriptive, real-world treatment patterns, resource use, and total cost of care among eculizumab- and ravulizumab-treated members with paroxysmal nocturnal hemoglobinuria
Broderick KC, Burke JP, Fishman J, & Gleason PP. (2023). Descriptive, real-world treatment patterns, resource use, and total cost of care among eculizumab- and ravulizumab-treated members with paroxysmal nocturnal hemoglobinuria. Journal of Managed Care & Specialty Pharmacy, 29(8), 941–951. doi: 10.18553/jmcp.2023.29.8.941
Paroxysmal
Comparative effectiveness of pegcetacoplan versus ravulizumab in patients with paroxysmal nocturnal hemoglobinuria previously treated with eculizumab: a matching-adjusted indirect comparison
Bhak RH, Mody-Patel N, Baver SB, et al. (2021) Comparative effectiveness of pegcetacoplan versus ravulizumab in patients with paroxysmal nocturnal hemoglobinuria previously treated with eculizumab: a matching-adjusted indirect comparison, Current Medical Research and Opinion, 37:11, 1913-1923, DOI: 10.1080/03007995.2021.1971182
Paroxysmal
Real-World Healthcare Resource Utilization (HRU) and Costs of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Receiving Eculizumab in a US Population
Cheng WY, Sarda SP, Mody-Patel N, et al. (2021) Real-World Healthcare Resource Utilization (HRU) and Costs of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Receiving Eculizumab in a US Population. Adv Ther. 38(8):4461-4479. doi:10.1007/s12325-021-01825-4
Paroxysmal
C3 inhibition with pegcetacoplan in subjects with paroxysmal nocturnal hemoglobinuria treated with eculizumab
de Castro C, Grossi F, Weitz IC, et al. C3 inhibition with pegcetacoplan in subjects with paroxysmal nocturnal hemoglobinuria treated with eculizumab. Am J Hematol. 2020;95(11):1334-1343. doi:10.1002/ajh.25960
Paroxysmal
Paroxysmal nocturnal hemoglobinuria: patient journey and burden of disease
Bektas M, Copley-Merriman C, Khan S, Sarda SP, Shammo JM. Paroxysmal nocturnal hemoglobinuria: patient journey and burden of disease. J Manag Care Spec Pharm. 2020;26(12-b Suppl):S8-S14. doi:10.18553/jmcp.2020.26.12-b.s8
Paroxysmal